The PARP inhibitor story began back in the mid-1990s, when a team of researchers at The Institute of Cancer Research – including our former Chief Executive Professor Alan Ashworth and Sir Mike ...

The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.